Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,624

Document Document Title
WO/2020/158687A1
In the present invention, a method for producing a compound of formula I comprises a step for causing a compound of formula III to undergo a Pechmann condensation reaction with respect to a compound of formula II in the presence of an or...  
WO/2020/125307A1
Disclosed is a method for constructing a Pseudomonas aeruginosa O11 serotype O antigen oligosaccharide using a D-glucose block, a L-fucosamine block and a D-fucosamine block, wherein the D-glucose block or the L-fucosamine block is conne...  
WO/2020/112647A1
This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.  
WO/2020/097188A1
Disclosed herein are compositions and methods for the identification of molecules capable of repressing NK-mediated killing of a target (donor) cell. The invention comprises the development and use of an assay to detect the effects of ta...  
WO/2020/077136A1
Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, w...  
WO/2019/094595A3
The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in met...  
WO/2019/036299A3
Methods of treating individuals who have cancer are disclosed. In some methods, the cancers may lack functional guanylyl cyclase C and/or p53. In some methods, the methods comprise protecting gastrointestinal cells from genotoxic damage ...  
WO/2020/058889A1
The present patent application relates to the use of an innovative amino acid derivative of glucosamine having the Formula 1 of the general structure which follows, or of a pharmaceutical composition which contains it as a single active ...  
WO/2020/052677A1
There is provided a peptide-containing compound that comprises a peptide component which is an amino acid sequence of from 2 to 45 amino acids, which peptide component is covalently bonded to one or more compounds of the formula (I), whe...  
WO/2020/051566A1
Although numerous investigations are focused on developing vaccines that induce protective humoral responses, fewer studies are aimed at developing vaccines that induce broad and robust T cell responses. In order to design a potent T cel...  
WO/2020/039984A1
The present invention addresses the problem of providing a compound library which has a higher percentage of biologically active compounds. This problem is solved by a compound library that includes cyclic peptides that comprise (i) an a...  
WO/2020/028744A1
Disclosed herein are chimeric receptors and precursors, chimeric antigen receptors and precursors, universal chimeric receptor cell precursors, chimeric antigen receptor T cells, and methods of constructing and using the same.  
WO/2020/004810A1
The present invention relates to a method for preparing a poly-γ-glutamic acid hydrogel by using ultraviolet rays, and a use of a poly-γ-glutamic acid hydrogel prepared by the preparation method. The method for preparing a poly-γ-glut...  
WO/2019/246392A1
The present disclosure provides a cytokine-based bioactivatable drug construct ("VitoKine") platform that aims to reduce systemic mechanism-based toxicities and lead to broader therapeutic utility for proteins and cytokines such as IL-15...  
WO/2019/240288A1
The present invention provides art that enables modification of an antibody, particularly regioselective modification of an antibody. More specifically, the present invention provides a substance having affinity for an antibody, and a co...  
WO/2019/199733A1
Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer.  
WO/2019/195859A1
The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for trea...  
WO/2019/110797A8
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: • a) amylin, an amylin receptor agonist or an amylin analog; • b) a co-polyamino acid be...  
WO/2019/176860A1
This cell adhesive material is obtained by modifying a substrate surface by using a peptide group comprising a peptide that contains: 40% to 75%, inclusive, of one or more types of basic amino acid residues selected from the group consis...  
WO/2019/135233A8
Disclosed herein is a process of preparing a polypeptide copolymer by polymerizing a mixture comprising N-carboxyanhydrides of alanine, tyrosine, carboxylate-protected glutamate and an amine-protected lysine, to form a protected polypept...  
WO/2019/135233A1
Disclosed herein is a process of preparing a polypeptide copolymer by polymerizing a mixture comprising N-carboxyanhydrides of alanine, tyrosine, carboxylate-protected glutamate and an amine-protected lysine, to form a protected polypept...  
WO/2019/117274A1
With regard to the present invention, it was discovered that a deprotection agent can be deactivated by a salt formed from a base and an acid having characteristics (i) and (ii), and as a result, excessive elongation of a peptide can be ...  
WO/2019/114159A1
A Camellia Oleifera meal polypeptide as well as a preparation method and an application thereof. The Camellia Oleifera meal polypeptide is prepared by taking Camellia Meiocarpa Hu. meal as raw materials, hydrolyzing the Camellia Meiocarp...  
WO/2019/110774A1
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: a basal insulin having an isoelectric point (pI) of between 5.8 and 8.5; b) and a co-polyami...  
WO/2019/110797A1
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: • a) amylin, an amylin receptor agonist or an amylin analog; • b) a co-polyamino acid be...  
WO/2019/102469A1
Anti-fogging proteinoid compounds are disclosed. Processes of preparing antifogging proteinoid compositions and incorporating thereof in or on a substrate are disclosed. Articles of manufacturing incorporating such compositions are also ...  
WO/2019/088167A1
Provided is a purification agent which comprises a compound having a betaine structure, and which is for a sugar chain having a length equal to or longer than that of a monosaccharide or for a glycopeptide having a sugar chain having a l...  
WO/2019/046699A1
The invention includes a bioelectronic interface comprising a self-assembling unit, wherein the self-assembling unit comprises a variant GPCR fusion protein bound to an S-layer fusion protein. The invention also encompasses a biosensor o...  
WO/2019/031446A1
[Problem] To provide a method and a composition for enhancing the immunogenicity of a polypeptide. [Solution] Provided is a composition containing a tagged polypeptide which is composed of a polypeptide, a spacer peptide bonded to a term...  
WO/2019/018238A1
In certain embodiments osteoadsorptive fluorogenic substrates of cathepsin K (or other proteases) are provided. Utilizing a bisphosphonate targeting moiety, the fluorogenic substrates provide effective bone-targeted protease sensor(s). I...  
WO/2018/225864A1
The present inventors found that, in screening a cyclic peptide compound capable of specifically binding to a target molecule, the hitting rate of a cyclic peptide compound capable of specifically binding to the target molecule can be im...  
WO/2018/159797A1
The present invention addresses the problem of providing: an embedding agent for a cell mass or a cell structure which allows the cell mass or the cell structure to be stably transported during transportation at low temperature, and allo...  
WO/2017/124921A9
The present invention provides a walnut oligopeptide powder, and a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt% or higher, wherein 95% or more of the peptides have a molecular weight...  
WO/2018/140974A1
Disclosed herein are methods, reagents, and pharmaceutical compositions for modulating immune effector cell activation that does not requirean antigen-specific antibody. The IgG Fc region is shown herein to contain both a domain that bin...  
WO/2018/088455A1
To develop a novel biomarker that is useful in diagnosing sepsis and provide a diagnostic agent and diagnostic method therefor. A method for diagnosing sepsis, said method comprising measuring a component selected from carbonic anhydrase...  
WO/2018/088541A1
The present invention provides a drug release means that is capable of independently controlling release of two or more kinds of drugs by supporting the drugs by a hydrogel which contains micelles of a cationic block polypeptide and mice...  
WO/2018/085846A1
The invention relates to multi-functional antibiotic agents formed from antibiotics conjugated to microbial membrane disrupting peptides. These antibiotic-peptide conjugates are designed so that the conjugate simultaneously functions as ...  
WO/2018/075885A1
Supramolecular structures comprising noncovalently associated peptide amphiphiles and lipids are provided. In particular, provided herein are supramolecular nanostructures of peptide amphiphiles and lipids, co-assembly of which is driven...  
WO/2018/057858A1
Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.  
WO/2018/017956A3
Provided are methods for producing recombinant adeno-associated virus (rAAV) vector particles at high recovery or high titer. Also provided are methods that concentrate rAAV vectors to a high concentration, for example, up to 5E+13 (5x10...  
WO/2018/042423A1
The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long ...  
WO/2018/006074A3
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2018/023028A1
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...  
WO/2018/014841A1
A self-assembled collagen and a preparation method therefor. The preparation method for the self-assembled collagen comprises the following steps: utilizing trypsin and papain in an enzymatic treatment of an animal-derived collagen so as...  
WO/2018/005608A1
In an aspect of the present application, compositions and methods are provided for preventing bone loss and/or stimulating bone healing in a subject in need thereof. Compositions can comprise a pharmaceutically acceptable carrier and a t...  
WO/2017/213158A1
The present invention addresses the problem of providing: a ribosome complex which can be prepared without involving a complicated reaction procedure, and in which a presented polypeptide is modified without impairing the function of a r...  
WO/2017/214076A1
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...  
WO/2016/176649A9
The present, invention provides a process for characterizing a glatiramer acetate related drug substance (GARDS) or a glatiramer acetate related drug product (GARDP) comprising separating a batch of a GARDS or GARDP according to hydropho...  
WO/2017/185250A1
Provided in the present application is a peptide containing the amino acid sequence YEKLTTLDTGGV (SEQ ID NO:1) or a functional variant thereof, the peptide being an active peptide for treating central nervous system injury. Also provided...  
WO/2017/181979A1
Disclosed is a mussel mucin or applications thereof in inhibiting organ inflammation. Specifically disclosed is the mussel mucin or the applications thereof in treating inflammation of the heart, stomach, intestines, lungs, liver, spleen...  

Matches 1 - 50 out of 1,624